Menu
Start Screening

Frontier mental health research: psychedelics & drug studies

Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.

Pharmacology Placebo Archives of General Psychiatry

1 paper

A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression

Carlos A. Zarate, Jaskaran Singh, Paul J. Carlson, Nancy E. Brutsché, Rezvan Ameli, David A. Luckenbaugh, et al.
Archives of General Psychiatry Summary & key facts 2006 3,698 citations

In a small, controlled study of 18 people with treatment-resistant major depression, a single intravenous dose of the NMDA receptor antagonist ketamine (0.5 mg/kg) produced rapid drops in depression scores. Improvement began within about 2 hours and remained statistically significant compared with placebo for up to 1 week. The study…

Neurotransmitter Receptor Influence on Behavior Treatment of Major Depression Tryptophan and brain disorders
Summaries and links are for general information and education only. They are not a substitute for reading the original publication or for professional medical, legal, or other advice. Always refer to the linked source for the full study.